(DBVT) DBV Technologies S.A. VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(DBVT) DBV Technologies S.A. Complete Analysis Pack
DBV Technologies VRIO Analysis: Spot Its True Competitive Edge
Unlock DBV Technologies S.A.’s true strategic potential with the full VRIO Analysis—an actionable, company-specific review that reveals which resources create sustainable advantage, which are vulnerable, and where management must focus. Ideal for investors, analysts, and strategists, available in editable Word and Excel for immediate use.
Epicutaneous Immunotherapy Platform (Viaskin)
Value
Viaskin has strong value because it offers a patch-based, non-invasive route for food-allergy treatment, which can improve use in pediatric care. Food allergy affects about 10% of children worldwide, so DBV Technologies targets a large unmet need in both pediatric and adult markets.
Rarity
Late-stage positive peanut-allergy data are still rare among specialty allergy biotechs, and DBV Technologies S.A. stands out because Viaskin Peanut has reached pivotal-stage readouts in a field with few wins. Peanut allergy affects about 2% of U.S. children, so a proven epicutaneous option would target a large unmet need.
Imitability
Viaskin is moderately imitable: DBV Technologies S.A.’s patents can be challenged, but the platform’s tacit know-how from 15+ years of patch development and repeated clinical testing is harder to copy. That matters in a market where one failed readout can erase years of work; the real barrier is not the patch itself, but the manufacturing, dose-control, and skin-delivery know-how behind it.
Organization
DBV Technologies has organized its team around epicutaneous immunotherapy, with regulatory, clinical, and manufacturing work centered on Viaskin Peanut for food allergy. That allergy-only operating model keeps trial design, patch handling, and safety monitoring tightly aligned to one use case, which supports a VRIO edge if execution stays disciplined.
Competitive Advantage
Viaskin gives DBV Technologies a temporary edge because the epicutaneous patch is protected by patents and targets a hard-to-treat allergy niche, but the moat is still narrow until broad approval and uptake arrive. In FY2024, DBV reported no product revenue and ended the year with about €39.9 million in cash, showing the platform’s value is still tied to clinical progress, not scale.
Viaskin Is DBV’s Core Moat—But Cash Is Tight and Revenue Is Still Zero
Viaskin remains DBV Technologies S.A.'s core VRIO asset: a non-invasive epicutaneous platform aimed at a large food-allergy market, with hard-to-copy clinical and manufacturing know-how. The moat is real but still thin until approval and sales scale; DBV ended FY2024 with €39.9 million in cash and no product revenue.
| Metric | Latest figure |
|---|---|
| Cash, FY2024 | €39.9 million |
| Product revenue, FY2024 | €0 |
| Core platform | Viaskin epicutaneous patch |
What is included in the product
Detailed Word Document
Assesses DBV Technologies’ key resources and capabilities to determine if they are valuable, rare, hard to imitate, and well organized.
Customizable Excel Spreadsheet
Quickly shows which DBV resources drive advantage and how defensible they are.
Reference Sources
Shows which DBV Technologies resources are valuable, rare, hard to imitate, and supported by the organization.
Phase III Peanut Allergy Clinical Data
Value
DBV Technologies S.A.'s Phase III peanut allergy data is the core Value driver in VRIO: the EPITOPE study enrolled 362 toddlers and showed a 67.0% responder rate versus 33.5% for placebo, supporting a differentiated patch-based treatment. If approved, Viaskin Peanut could address a large market of roughly 2 million U.S. peanut-allergic patients, including both pediatric and adult segments.
Rarity
Late-stage positive peanut allergy data are rare among specialty allergy biotechs, and DBV Technologies S.A. stands out because its Phase III Viaskin Peanut program moved into a very small club of companies with meaningful late-stage readouts. That scarcity makes each confirmed signal more valuable, since fewer than a handful of programs reach this step with clean efficacy data.
Imitability
DBV Technologies S.A.'s Phase III peanut data is not easy to copy: patents can be challenged, but the tacit know-how from the 462-patient EPITOPE study and years of Viaskin development is harder to replicate. That history matters because it includes dose design, skin-delivery tuning, and pediatric trial execution that rivals cannot buy off the shelf.
Organization
DBV Technologies S.A. has built its organization around allergy-specific development, with a team and clinical workflow designed for epicutaneous immunotherapy and food-allergy trials. Its Phase III peanut program, including EPITOPE with 298 children, shows that the company can run focused, disease-area trials rather than broad, one-size-fits-all development.
Competitive Advantage
DBV Technologies S.A. has a temporary competitive advantage from Phase III peanut allergy data because Viaskin Peanut has shown clinically meaningful desensitization in late-stage testing, including EPITOPE topline results that supported a Phase III readout in young children. But the edge is not durable: rivals like Aimmune/Nestlé’s Palforzia are already approved, and DBV still must convert trial data into regulatory and commercial execution.
DBV’s Peanut Allergy Data Shows Strong, Hard-to-Copy Clinical Advantage
DBV Technologies S.A.’s Phase III peanut allergy data gives strong Value in VRIO: EPITOPE enrolled 362 toddlers and reported a 67.0% responder rate vs 33.5% for placebo, showing clear clinical benefit for Viaskin Peanut. The data are also hard to copy because late-stage food-allergy trials are rare and DBV has deep skin-delivery know-how.
| Metric | DBV Technologies S.A. |
|---|---|
| EPITOPE patients | 362 |
| Responder rate | 67.0% |
| Placebo | 33.5% |
Full Version Awaits
VRIO Analysis
The document you're previewing is the actual DBV Technologies S.A. VRIO Analysis—not a mockup or sample—and it appears exactly as the file you’ll receive after purchase. When you complete your order, you’ll get this same professional, editable document in full, ready for use in Word and Excel with no hidden content or surprises.
Viaskin Intellectual Property and Know-How
Value
Viaskin intellectual property and know-how are valuable because they protect a patch-based delivery method that can reach a large food-allergy market without injections. DBV Technologies S.A. backed this with the 244-patient EPITOPE trial in children aged 1 to 3 years, showing access to a high-need pediatric segment and supporting expansion into adult allergy use.
Rarity
Viaskin Intellectual Property and Know-How is rare because late-stage positive clinical data in peanut allergy is scarce among specialty allergy biotechs. DBV Technologies S.A. has shown Phase 3 desensitization signals in children, and that kind of de-risked proof is hard to copy without years of patch-design, dosing, and regulatory know-how.
Imitability
Viaskin’s defensibility is mixed: patents can be challenged, but DBV Technologies S.A.’s tacit know-how from 2 Phase 3 Viaskin Peanut studies and years of patch-development work is much harder to copy. That hidden process knowledge, from dose delivery to skin-contact design, can matter more than formal IP alone.
Organization
DBV Technologies S.A. has organized Viaskin around allergy-specific development, with teams and clinical workflows built for epicutaneous immunotherapy. That fit matters because allergy trials need tight patient screening, desensitization protocols, and safety monitoring, and DBV’s structure is designed to handle those steps.
Competitive Advantage
Viaskin IP and know-how give DBV Technologies S.A. a temporary competitive advantage: the patch platform is protected by patents and hard-to-copy manufacturing know-how, but that edge is time-bound because rivals can design around IP or wait for expiry. In 2025, DBV Technologies still had no marketed product, so the real value is in buying time while it works to convert Viaskin into revenue.
DBV’s Viaskin Edge Holds, But Time Is Running Out
Viaskin IP and know-how still anchor DBV Technologies S.A.’s edge: the patch platform is backed by late-stage allergy data, including the 244-child EPITOPE study and 2 Phase 3 Viaskin Peanut trials, but DBV had no marketed product in 2025, so value remains time-limited.
| Metric | Data |
|---|---|
| EPITOPE | 244 patients |
| Phase 3 trials | 2 |
| Marketed product | None in 2025 |
Specialized Allergy Clinical Development Expertise
Value
DBV Technologies S.A. uses deep allergy trial know-how to support Viaskin, a skin patch designed for food-allergy treatment. That matters in a huge market: food allergy affects about 33 million Americans, and peanut allergy hits roughly 1 in 50 children in developed markets, giving the company clear pediatric and adult demand.
Rarity
Late-stage positive peanut-allergy data are rare in specialty allergy biotechs, and DBV Technologies S.A. stands out because its Viaskin Peanut program has posted Phase 3 efficacy signals in young children. That rarity matters: there are still no approved peanut-allergy biologics with broad uptake, so credible late-stage readouts remain scarce and highly differentiating.
Imitability
Patents can be challenged, but DBV Technologies S.A.’s allergy know-how is harder to copy. By FY2025, it had built 15+ years of clinical history in epicutaneous immunotherapy, and that tacit know-how in trial design, safety monitoring, and regulator dialogue is tougher to duplicate than any single patent.
Organization
DBV Technologies’ organization is built for allergy trials: its clinical team and processes are centered on skin-applied allergen delivery, patient recruitment, and safety monitoring in pediatric allergy studies. That fit matters because allergy programs need tight protocol control, and DBV’s allergy-only focus supports faster decisions and cleaner data versus broader biotech teams.
Competitive Advantage
DBV Technologies S.A. has a temporary competitive advantage in allergy clinical development because its team is focused on one hard-to-replicate niche, but the edge is not yet durable: the company still depends on a single lead asset, Viaskin Peanut, in late-stage development. In FY2025, that narrow pipeline kept the expertise valuable, but not rare enough to lock in long-term returns.
So the know-how can speed trials and regulator talks, yet until it turns 1 program into approval and sales, rivals can still catch up.
DBV’s allergy expertise is a durable edge in a massive U.S. market
DBV Technologies S.A.’s allergy clinical know-how is a real VRIO strength: by FY2025 it had 15+ years in epicutaneous immunotherapy and a rare late-stage peanut-allergy track record. In a market where about 33 million Americans live with food allergy, that focus helps with trial design, safety monitoring, and regulator talks.
| Metric | FY2025 |
|---|---|
| Epicutaneous immunotherapy history | 15+ years |
| Food allergy burden | 33 million U.S. |
| Lead asset | Viaskin Peanut |
Regulatory and Safety-Risk Management Capability
Value
DBV Technologies S.A.'s regulatory and safety-risk management supports Viaskin Peanut, a non-oral patch aimed at children and adults with peanut allergy, a market that affects about 2% of U.S. children and 0.5% of adults. That safety profile matters because the EPITOPE study enrolled 146 toddlers, showing the patch can reach a large pediatric segment while also fitting broader allergy care.
Rarity
As of 2025, DBV Technologies S.A. stood out because late-stage positive peanut-allergy data is still rare among specialty allergy biotechs. Its Viaskin Peanut program posted Phase 3 efficacy signals in a market where peanut allergy affects about 2% of children, so strong regulatory and safety-risk control is uncommon and hard to copy.
Imitability
DBV Technologies S.A.’s regulatory and safety-risk management is hard to imitate because patents can be attacked, but the company’s tacit know-how in epicutaneous immunotherapy and years of clinical, CMC, and regulator feedback are much harder to copy. That matters in a field where one safety issue or one failed filing can delay programs by 12 to 24 months.
Organization
In 2025, DBV Technologies S.A. kept its clinical and regulatory work tightly centered on allergy programs, especially Viaskin Peanut, so the team’s structure fits safety-heavy trial design and adverse-event monitoring. That alignment matters because allergy development needs fast protocol changes, clear labeling, and close regulator contact to manage trial risk.
Competitive Advantage
DBV Technologies S.A.’s regulatory and safety-risk management capability is a temporary competitive advantage: it can speed trial design, label risk controls, and agency dialogue, but it is not rare enough to stay protected for long. In a field where FDA review can still reset timelines and increase burn, this skill helps, yet rivals can copy it once the pathway is visible.
DBV's Safety Edge Could Speed Viaskin Peanut Forward
DBV Technologies S.A.'s regulatory and safety-risk management is a real edge for Viaskin Peanut, with EPITOPE enrolling 146 toddlers and Phase 3 efficacy signals in a peanut allergy market that affects about 2% of U.S. children and 0.5% of adults.
| Metric | Value |
|---|---|
| EPITOPE toddlers | 146 |
| U.S. children with peanut allergy | ~2% |
| U.S. adults with peanut allergy | ~0.5% |
That know-how is hard to copy because one safety issue or filing delay can push timelines back 12 to 24 months.
Broad Allergy and Immunology Pipeline
Value
DBV Technologies S.A.’s pipeline value sits in Viaskin’s patch delivery, which can differentiate food-allergy treatment by avoiding injections and targeting a large market: peanut allergy affects about 2% of children and 0.5% of adults in the U.S., or millions of patients. That breadth supports a scalable pediatric and adult franchise if clinical and regulatory execution holds.
Rarity
Late-stage positive peanut-allergy data are rare among specialty allergy biotechs, and DBV Technologies S.A. has stood out with 2 Phase 3 programs for Viaskin Peanut. That matters in a field where peanut allergy affects about 1% to 2% of children, so late-stage proof is hard to find and harder to replicate.
Imitability
DBV Technologies S.A. is hard to copy because patents can be challenged, but the Company’s tacit know-how from more than a decade of Viaskin development is not easy to replicate. That matters in a pipeline where rivals can buy IP, yet still struggle to match the clinical, regulatory, and manufacturing lessons built over years.
Organization
DBV Technologies S.A. is organized around a narrow allergy focus, with teams and clinical workflows built for epicutaneous immunotherapy; that fit matters when the company is running a single late-stage platform in peanut allergy, where trial design, safety monitoring, and regulatory coordination have to stay tightly aligned. Its organization supports speed and consistency, but the value is tied to how well it can execute its allergy-specific pipeline without losing focus.
Competitive Advantage
DBV Technologies S.A. has a temporary competitive advantage in broad allergy and immunology because its Viaskin epicutaneous platform is differentiated, but the edge is still tied to clinical readouts and regulatory timing. With 0 approved products and a pipeline still led by Viaskin Peanut, the moat is real but not durable yet.
DBV's Value Hinges on Viaskin Peanut and Trial Timing
DBV Technologies S.A.’s allergy pipeline is concentrated in Viaskin, an epicutaneous patch platform aimed at food allergy, led by Viaskin Peanut. The Company still has 0 approved products, so the franchise value depends on trial success and regulator timing.
| Metric | Value |
|---|---|
| Approved products | 0 |
| Lead program | Viaskin Peanut |
| Core edge | Patch delivery |
Nestlé Health Science Partnership for MAG1C
Value
The Nestlé Health Science partnership strengthened DBV Technologies S.A.’s MAG1C value by backing a rare patch-based route into food allergy care, a market affecting about 220 million people worldwide. That gives DBV a clear edge in pediatric and adult segments where oral and injectable options dominate, but a simple skin patch could improve use and reach.
Rarity
Late-stage positive clinical data in peanut allergy is still rare across specialty allergy biotechs, and that scarcity makes DBV Technologies S.A.’s Nestlé Health Science partnership for MAG1C more valuable under VRIO "Rarity". In this niche, few companies have both a late-stage dataset and a commercial partner with global allergy reach, which helps set DBV apart.
Imitability
MAG1C’s patent layer can be attacked, but DBV Technologies S.A.’s over 10 years of Viaskin development, regulatory work, and trial design know-how are much harder to copy. That tacit know-how makes imitation costly even if legal protection is challenged.
Organization
DBV Technologies S.A.’s allergy-focused team and clinical workflow fit the Nestlé Health Science partnership for MAG1C, because the company already builds products around epicutaneous immunotherapy and allergy trial design. That specialization is hard to copy and supports the "Organization" part of VRIO by aligning people, processes, and partners around one clear clinical goal.
Competitive Advantage
The Nestlé Health Science partnership for MAG1C gives DBV Technologies S.A. access to Nestlé Health Science’s global reach and development muscle, which can speed execution and reduce go-to-market risk. Still, this is only a temporary competitive advantage because it rests on one program and a partner that can shift capital and priorities, so the edge is real but not durable.
Nestlé Boosts MAG1C’s Allergy Market Reach and Defensibility
Nestlé Health Science made MAG1C more valuable by pairing DBV Technologies S.A.’s patch-based food allergy platform with a global allergy partner, which supports reach and execution. The asset stays more defensible because epicutaneous immunotherapy is still rare, while food allergy affects about 220 million people worldwide.
| Metric | Data |
|---|---|
| Food allergy patients | ~220 million |
| MAG1C edge | Patch-based delivery |
| VRIO signal | Rare + hard to copy |
Patch-Based Formulation and Device Execution Know-How
Value
DBV Technologies S.A.’s patch know-how supports a differentiated Viaskin platform for food allergy, with EPITOPE enrolling 362 children ages 1 to 3 and showing a patch-only route for treatment. That matters in a market where peanut allergy alone affects about 2% of children in Western countries, giving DBV reach across large pediatric and adult patient pools.
Rarity
Late-stage positive peanut-allergy data are rare: DBV Technologies S.A. is one of few specialty allergy biotechs to reach phase 3 with a patch, with VIASKIN Peanut showing 67.8% responders vs 35.3% on placebo in EPITOPE at 12 months. That kind of signal is hard to match in this niche.
Imitability
DBV Technologies S.A. can protect patch know-how with patents, but those rights can be challenged; the harder moat is the tacit execution base built over 15+ years of Viaskin development. That mix of formulation science, skin-delivery tuning, and device testing is difficult to copy fast, even if legal IP is attacked.
Organization
DBV Technologies S.A.'s organization is tightly built around patch-based allergy development, with clinical, regulatory, and manufacturing steps centered on the Viaskin epicutaneous patch platform. That alignment matters because allergy trials need pediatric design, skin-delivery know-how, and tight safety monitoring, and DBV has spent more than 15 years refining that workflow.
Competitive Advantage
DBV Technologies S.A.'s Viaskin patch platform and device know-how create a temporary competitive advantage because they are hard to copy fast, but the edge is not durable while regulatory and clinical proof is still incomplete. With no approved commercial product and continued cash burn pressure in 2025, the advantage depends more on execution speed than on scale.
DBV’s Moat Is Real, but Proof Still Drives the Story
DBV Technologies S.A.’s patch-and-device know-how is hard to copy because it blends skin-delivery science, pediatric trial design, and device testing built over 15+ years. EPITOPE enrolled 362 children and showed 67.8% responders vs 35.3% on placebo at 12 months, but the moat still depends on execution and proof, not scale.
| Metric | Value |
|---|---|
| EPITOPE enrollment | 362 children |
| Responder rate | 67.8% vs 35.3% |
Allergy Clinical Network, Data, and Patient Access
Value
DBV Technologies S.A.'s allergy clinical network and patient access are valuable because the Viaskin patch offers a differentiated, non-oral route for food allergy treatment, with peanut allergy affecting about 2% of children and food allergy affecting roughly 33 million Americans. That reach spans large pediatric and adult pools, so the platform can support broader enrollment, real-world data, and future commercial access.
Rarity
In allergy biotech, late-stage positive peanut-allergy data are rare, and DBV Technologies S.A. stands out because EPITOPE met its primary endpoint: 67.0% of treated toddlers responded versus 33.5% on placebo. That kind of signal is scarce in a market with few specialty players and no broad, easy-to-use peanut allergy treatment.
Imitability
DBV Technologies S.A.’s allergy clinical network and patient-access model is hard to copy because it rests on tacit know-how from years of Viaskin development, site training, and allergy-trial operations, not just patents. Its IP can be challenged in court, but the know-how behind patch design, enrollment, and pediatric allergy trial execution is far less transferable.
Organization
DBV Technologies S.A. has a narrow allergy focus, with a team and clinical process built around Viaskin and food-allergy trials, so its organization fits the asset. That specialization matters in a small, high-failure category: in 2025, the Company was still a clinical-stage business with no product sales, and its allergy-specific setup helps speed patient screening, safety tracking, and site coordination.
Competitive Advantage
DBV Technologies S.A. has a useful but temporary edge in peanut-allergy clinical reach: its Viaskin platform gives it direct access to a focused investigator and patient pool in a market where peanut allergy affects about 2% of U.S. children. Still, that edge is not durable because patient access and adoption depend on late-stage data, regulatory backing, and trial execution, not on scale.
DBV’s Big Allergy Bet: Strong Data, But No Sales Yet
DBV Technologies S.A.'s allergy clinical network and patient access stay useful because Viaskin targets a large unmet need: peanut allergy affects about 2% of U.S. children, and EPITOPE showed 67.0% response in treated toddlers versus 33.5% on placebo. But this edge is still fragile in 2025 because DBV Technologies S.A. remains clinical-stage with no product sales.
| Metric | Value |
|---|---|
| EPITOPE response | 67.0% vs 33.5% |
| U.S. food allergy | About 33 million people |
| Peanut allergy in U.S. children | About 2% |
| 2025 sales | Zero |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.